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1. Introduction 
Lung cancer patients with HIV infection are expected to become an emerging issue with respect 
to morbidity and mortality, as the number of such patients is rapidly increasing. However, few 
reports or textbooks dealing with this issue have documented the details of these cases. Thus, in 
clinical settings, infectious disease physicians or medical oncologists occasionally hesitate to 
treat HIV-infected patients with lung cancer. Since 1996, the outcome of HIV-infected patients 
has improved, because CD4 cell counts and viral load are generally well controlled with the 
advent of highly active antiretroviral therapy (HAART), which strongly inhibits HIV viral 
proliferation and restores the patient’s immunological status. Furthermore, the prognosis in the 
HIV population has improved significantly due to the prevention and treatment of 
opportunistic infections (OIs). As a result, HIV infection is chronically manageable. In the pre-
HAART era, the median survival time in the HIV population was 10 years, while, at present, 
85% of patients survive more than 10 years.(Sepkowitz, 2001) 
In the pre-HAART era, most HIV-infected patients died of acquired immunodeficiency 
syndrome (AIDS). Recently, however, one-third of all such patients die of malignant 
tumor,(Bonnet et al., 2009) and deaths due to AIDS-defining cancers (ADCs), such as Kaposi’s 
sarcoma (KS), primary central nervous system lymphoma (PCNSL) and non-Hodgkin’s 
lymphoma (NHL), and invasive cervical carcinoma, which were defined by the Centers for 
Disease Control and Prevention (CDC), are decreasing. On the other hand, the number of 
deaths due to non-AIDS-defining cancers (NADCs) is increasing.(Engels et al., 2008, Silverberg 
et al., 2009) At present, in the population with HIV infection, lung cancer accounts for 5% of all 
deaths and 15% of all deaths by malignant tumors.(Bonnet et al., 2009) Of all of the NADCs, 
lung cancer is the most common,(Engels et al., 2006, Lavole et al., 2006, Patel et al., 2008) followed 
by breast cancer, soft tissue sarcoma, Hodgkin’s lymphoma (HL), penile cancer, lip cancer, and 
testicular seminoma.(Frisch et al., 2001) In 1984, Irwin et al. reported the first case with 
simultaneous HIV infection and lung cancer,(Irwin et al., 1984) and several dozen patients have 
since been reported in the United States and Europe. (Table. 1) The clinical demographics of 
lung cancer with HIV infection differ slightly from the general population and are characterized 
by younger age, advanced stage at diagnosis, and aggressive tumor extension. Thus, the 
prognosis of lung cancer in the HIV population is poorer than that of lung cancer in the general 
population.(Lavole et al., 2006) Moreover, patient fragility to treatment needs to be considered. 
In the general population, lung cancer is the most common cause of cancer death 
worldwide. Furthermore, in the last decade, there has been progress in lung cancer 
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treatment modalities. The development of novel antitumor agents and molecular targeted 
drugs has increased the lines of chemotherapy, and new treatment strategies, such as 
maintenance therapy and biomarker-based therapy (personalized therapy), provide diverse 
options. At present, in front-line chemotherapy for lung cancer patients, platinum-doublet 
chemotherapy with the third-generation antitumor agent has been shown to prolong 
survival and contribute to symptom palliation. Before the 1990s, the median survival time 
with the best supportive care was 4-5 months, and the 1-year survival rate was 10% in Stage 
IV non-small cell lung cancer (NSCLC). In 1995, the benefits of chemotherapy for Stage IV 
NSCLC were confirmed, and the median survival time was prolonged to 8 months.(Non-
small Cell Lung Cancer Collaborative Group, 1995) At present, median survival time is 12 
months, and the 1-year survival rate has improved to 50-60% from 30-35% in 2002.(Azzoli et 
al., 2009) Thus, the reported data dealing with lung cancer in HIV patients are not 
comparable. In addition, drug interactions between antiviralagents and antitumor agents  
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Sridhar et al. 19 86-91 47 100 94 60 21 32 95 42 31 5 121 53 - 37 79 3 
Trielli et al. 36 86-98 38 89 94 40 69 17 86 36 33 14 150 44 - 43 84 5 
Brock et al. 92 86-04 46 67 99 30 58 - 91 48 17 9 305 - 5.5 - 87 6.3 
Vyzula et al. 16 88-95 45 94 100 30 63 38 88 50 19 12 184 54 - 69 81 5.4 
Alshafie et al. 11 90-94 50 82 90 - 81 0 100 46 36 0 329 30 - - 90 3 
Spano et al. 22 93-02 45 86 95 40 23 45 95 36 50 5 364 30 - - 90 3 
Pakkala et al. 80 95-08 52 80 100 37 25 33 91 41 32 9 304 - - - - - 
Lavole et al. 49 96-07 46 67 99 33 17 18 100 67 17 0 350 - 8.6 71 84 8.1 
D’Jaen et al. 75 96-08 50 83 99 41 30 47 81 46 35 19 340 - 11 - 77 9 
Bertolaccini et al. 26 03-07 39 85 85 30 58 23 81 - - 19 143 - - - 76 23 
IVDU: intravenous drug user; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; PS: 
performance status 
Table 1. Documented clinical demographics of lung cancer patients with HIV. 
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must be considered, as they may increase or decrease efficacy by inhibiting cytochrome P450 
(CYP450) induction, and the actual efficacy of and tolerance to therapy in such patients are 
uncertain. 
In this chapter, we discuss the epidemiology, frequency, risk factors, clinical management, 
and treatment of HIV-infected lung cancer patients. 
2. Incidence 
Between 2001 and 2006, 71% of deaths were due to malignant tumors, as compared to 
only 20% in the pre-HAART era.(Crum-Cianflone et al., 2009) It is evident that the HIV-
infected population has a higher risk for lung cancer. In many studies comparing the 
incidence of lung cancer in patients with HIV to that in the general population, the 
standardized incidence ratio (SIR), adjusted for age and sex, has been calculated. SIR is an 
estimate of the ratio of the incidence of cancer in a given patient subset compared with the 
projected cancer incidence in the population at large. For instance, an SIR > 1 would 
indicate that lung cancer occurs more frequently in HIV-infected patients than in the 
general population; in fact, the SIR was 1.4-4.5. In the period before the advent of HAART, 
the SIR was 6.5 (95% confidential interval (CI) 4.5-8.9),(Frisch & Hjalgrim, 1999, Parker et 
al., 1998) from 1978-1996, the SIR was 4.5 with 808 patients,(Frisch et al., 2001) and in most 
European studies, the SIR did not exceed 1.13.(Bower et al., 2003, Herida et al., 2003, 
Powles et al., 2009) In the HAART era, the SIR was 2.27-3.3.(Powles et al., 2009, Patel et al., 
2008) In a meta-analysis with seven observational studies of NADCs (n=1016), the SIR 
was 2.72 (95% CI 1.91-3.87).(Grulich et al., 2007) In many studies, the number of lung 
cancer patients with HIV infection has been shown to increase from the HAART era to the 
post-HAART era. The incidence, however, has not changed. On the other hand, there are 
few data from Asian countries. The TAHOD study, a retrospective study of 617 patients 
between 2000 and 2008 in 10 Asian countries, reported that the number of patients with 
simultaneous HIV infection and NADCs is increasing, even in developing countries. 
Infection-unrelated NADCs (NADC-IURs), including lung cancer, account for 22%, with 
lung cancer being the most common (1.9%, 12 patients). In this study, the authors 
concluded that the Asian patient demographic differs from the Western 
demographic.(Petoumenos et al., 2010) 
3. Pathogenesis & risk factors 
The risk factors for lung cancer in the HIV population are strongly associated with 
immunity and cigarette smoking. The higher risk for carcinogenesis in immune-
compromised patients and the increased risk for lung cancer occurrence are particularly 
well known; kidney transplant patients have a significantly higher incidence of lung cancer 
than hemodialysis patients.(Vajdic et al., 2006) Carcinogenesis in lung cancer is not directly 
associated with viral load and CD4 cell counts, and the mechanism of the increased risk for 
lung cancer is not fully understood. The reasons for the increased incidence of lung cancer 
in HIV-infected patients therefore remain uncertain. 
3.1 Smoking exposure & other traditional risk factors 
Cigarette smoking in the HIV population is a major contributing factor for carcinogenesis, as 
in the general population. The American Lung Association has reported that 87% of all lung 
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cancer is caused by smoking, and smoking cessation decreases the annual risk.(Samet et al., 
1988) The rate of smoking in the HIV population is 57%, higher than in the general 
population (33%),(Saves et al., 2003) and a smoking history of 30-40 pack-years is seen in the 
HIV population.(Benard et al., 2007, Friis-Moller et al., 2003) In particular, in the Women's 
Interagency HIV Study (WIHS) cohort study in the HIV population in the United States, 
female lung cancer patients with HIV infection were significantly more common than in the 
general population, showing the increased risk for lung cancer.(Levine et al., 2010) Thus, 
smoking cessation programs need to be directed to the HIV population when infection is 
diagnosed. On the other hand, smoking is reported to be an independent risk factor for 
carcinogenesis in lung cancer.(Kirk et al., 2007) 
Recently, the National Cancer Institute reported that an annual low-dose computed 
tomography (CT) scan in the general population decreased lung cancer death by 80% by 
detecting the early stages of lung cancer.(Aberle et al., 2010) In a study at Johns Hopkins 
University and associated hospitals, most of the 92 lung cancer patients with HIV infection 
died of lung cancer. Overall, 60% of the 32 patients who underwent chest radiography were 
not diagnosed as having lung cancer within a year. With regard to CT, 1 out of 28 patients 
was not diagnosed.(James, 2006) Smoking cessation and low-dose CT scans to detect the 
early stages of lung cancer would therefore be beneficial for HIV population. 
Among other behavioral risk factors, intravenous drug users had been considered as a 
higher risk for developing lung cancer. However, the higher rate of smoking among 
intravenous drug users may be a confounding factor in some studies. 
3.2 Immunosuppression as a risk factor 
Immunodeficiency is a significant risk factor for carcinogenesis in some types of cancer. 
However, there is no evidence that decreased CD4 cell counts are associated with 
carcinogenesis in NADCs.(Clifford & Franceschi, 2007) In many case-control studies, the 
incidence of NADCs was not associated with the CDC classification (Table 2).  
 
CD4 Cell 
Categories 
Clinical Categories 
A 
Asymptomatic, Acute 
HIV, or PGL 
B 
Symptomatic 
Conditions, not A or C 
C 
AIDS-
Indicator 
Conditions 
>500/µL A1 B1 C1 
200-500/µL A2 B2 C2 
< 200/µL A3 B3 C3 
CDC = U.S. Centers for Disease Control and Prevention; PGL = persistent generalized 
lymphadenopathy.  
Table 2. CDC Classification System for HIV-Infected Adults and Adolescents 
However, the incidence in HL, anal cancer, or hepatocellular carcinoma is affected by 
decreased CD4 cell counts. CD4 cell counts less than 200 cells/µL were associated with the 
incidence of NADCs (hazard ratio (HR), 1.67).(Powles et al., 2009) CD4 cell counts increased 
by 100 cells/µL with the introduction of HAART, and the risk for NADCs decreased by 
19%.(Bruyand et al., 2009) However, carcinogenesis in lung cancer is not considered to be 
associated with immunological status (CD4 cell counts and viral load).(Kirk et al., 2007, 
Spano et al., 2004) 
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3.3 HIV as a risk factor 
Many cases of carcinogenesis in HIV-related carcinomas are related to viruses such as 
Epstein Barr virus or Human Herpes virus-8. The International Agency for Research on 
Cancer (IARC), an agency of the World Health Organization (WHO), is examining the 
relationship between viruses and carcinogenesis, including: Epstein Barr virus for HL, NHL, 
nasopharyngeal carcinoma, and Burkitt’s lymphoma; human herpes virus-8 for KS and 
primary effusion lymphoma; human papilloma virus for cervical, vulvar, and vaginal 
carcinoma, penile carcinoma, anal carcinoma, oral cavity carcinoma, and oropharyngeal and 
tonsillar carcinoma; hepatitis C virus for hepatocellular carcinoma and NHL; hepatitis B 
virus for hepatocellular carcinoma; and HIV for cervical and conjunctival squamous cell 
carcinoma, NHL, PCNSL, KS, and HL (particularly mixed cellularity and lymphocyte 
depleted subtypes). Of these, HIV is not organ-specific and is unique in that carcinogenesis 
occurs indirectly through immune suppression. Considering immunological status and 
infection, carcinomas accompanying HIV infection are classified into three categories: first, 
KS, NHL, and head and neck cancer, including AIDS-defining disease; second, NADC-IRs 
(infection-related), related to infection, hepatocellular carcinoma, HL, leiomyosarcoma, anal 
cancer, bladder cancer, laryngeal cancer, oral cavity cancer, penile cancer, gastric cancer, 
tongue cancer, and tonsillar cancer; and lastly, NADC-IURs (infection-unrelated), not 
related to infection, such as lung cancer and breast cancer. 
Currently, carcinogenesis in lung cancer is considered not to be associated with HIV 
infection itself. On the other hand, microsatellite alternation resulting in genetic instability is 
seen in lung cancer patients with HIV infection.(Wistuba et al., 1998) In another study, HIV-
infected patients easily developed pulmonary disease because of decreased glutathione and 
antioxidant levels, as well as increased lysosome and chemokine ligand 5 (CCL5) levels in 
broncho-alveolar lavage fluid.(Agostini et al., 1995, Allard et al., 1998, Buhl et al., 1989, 
Gordon et al., 2005) Chronic inflammation is associated with carcinogenesis in lung 
cancer.(Buhl et al., 1989) (Fig. 1) Furthermore, downregulation of HIV Tat-interacting protein  
 
 
Fig. 1. Potential mechanisms for carcinogenesis in non-AIDS-defining cancer(Nguyen et al.) 
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30 (TIP30) has been verified to promote metastasis of lung cancer in vitro and in nude 
mice.(Baker et al., 2000, Tong et al., 2009) Thus, lung cancer in the HIV population tends to 
be aggressive with poor prognosis. Inhibiting HIV appears to inhibit carcinogenesis in lung 
cancer; however, there is no clear evidence of decreased incidence of lung cancer with the 
use of HAART. HAART reconstitutes immunity and decreases the risk of OIs. 
4. Clinical manifestations 
When compared to lung cancer in the general population, lung cancer in HIV-infected 
patients affects younger patients and is more aggressive. The median age of HIV-infected 
lung cancer patients is 45-50 years, while it is 62 years in the general population.(Spano et al., 
2004) With regard to the clinical stage of the lung cancer, 75-90% of all HIV-infected patients 
are advanced, 18-29% are in a locally advanced stage, and 50-68% are in the metastatic 
stage.(Lavole et al., 2006) Adenocarcinoma is the most common (31-52%), followed by 
squamous cell carcinoma (17-39%), large cell carcinoma (3-16%), small cell carcinoma 
(SCLC) (1-14%), and bronchial alveolar carcinoma (less than 2%).(Tirelli et al., 2000, Vyzula 
& Remick, 1996, Sridhar et al., 1992, Alshafie et al., 1997, D'Jaen et al., 2010) This is similar to 
the distribution seen in the general population, as NSCLC accounts for 85% of all lung 
cancer patients in the general population. Comparing the pre-HAART era and the HAART 
era, the rate of adenocarcinoma was unchanged (48%), but the rate of squamous cell 
carcinoma was 21% in the pre-HAART era, as compared to 10% in the HAART era.(Brock et 
al., 2006) Epidermal growth factor receptor (EGFR) mutation is a predictive factor for EGFR-
tyrosine kinase inhibitors (EGFR-TKIs), and the incidence of harboring EGFR mutation 
among Asians is 30-35%, while it is ~10% among Caucasians.(Maemondo et al., 2010, 
Mitsudomi et al., 2009, Rosell et al., 2009) A lung cancer patient harboring EGFR mutations 
with HIV infection has been reported.(Erickson et al., 2008) CD4 cell counts at diagnosis 
range between 120 and 360 cells/µL,(Spano et al., 2004, Tirelli et al., 2000, Vyzula & Remick, 
1996, Sridhar et al., 1992, Brock et al., 2006, Bedimo et al., 2009, Tenholder & Jackson, 1993) 
while median CD4 cell counts in the HAART era are more than 300 cells/µL. 
Overall, 25-50% of lung cancer patients with HIV infection had AIDS,(Alshafie et al., 1997, 
Lavole et al., 2006, Spano et al., 2004, Sridhar et al., 1992, Tirelli et al., 2000, Vyzula & Remick, 
1996) and 55% underwent HAART. The latency from diagnosis of HIV infection to the 
diagnosis of lung cancer differs by sex, being 4.1 years in women and 7.7 years in men 
(p=0.02). However, the gender-based difference has not been discussed.(Pakkala et al., 2010) 
The frequency of metastatic organ involvement is uncertain. Release of interleukin-1 by 
intracerebral gp-120 components with HIV promotes brain metastasis in vivo.(Hodgson et 
al., 1998) In the clinical setting, a patient with two intracerebral hemorrhages has been 
reported (the incidence of intratumoral hemorrhage in NSCLC is 0.52%).(Okuma et al., 2010) 
Of note, HIV-infected patients have a higher risk of intracranial events(d'Arminio Monforte 
et al., 2004); thus, careful follow-up is required for HIV-infected patients in clinical settings. 
5. Multidisciplinary treatments & management 
The fundamental modalities of treatment for lung cancer are surgery, radiotherapy, and 
chemotherapy. 
SCLC is sensitive to both chemotherapy and radiotherapy; thus, radical concurrent 
chemoradiotherapy is indicated for limited-disease SCLC. When compared to NSCLC, 
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SCLC is characterized by higher grade, rapid progression with proliferation, and ease of 
metastasis to lymph nodes/distant organs in the early stage. Untreated, the median survival 
time is between 2 and 4 months. The response rate and median survival time in limited-
disease SCLC are 70% and between 14 and 20 months, respectively. In extended-disease 
SCLC, chemotherapy is basic, and palliative radiotherapy is added according to the 
symptoms. The response rate in extended disease is 45-95%, and the median survival time is 
7-10 months.(El Maalouf et al., 2007) 
In NSCLC, radiotherapy or chemotherapy is less sensitive than SCLC. Radical surgery is 
limited in Stage I-III NSCLC, and palliative chemotherapy is indicated in Stage IV NSCLC, 
while surgery alone is for Stage IA, and surgery-based multidisciplinary treatment is 
required in Stage IB-III. A decision on the treatment strategy should take into account 
histology, age, performance status (PS), and co-morbidities. In Stage IV patients with poor 
PS (≥ 3) best supportive care is recommended. The 5-year survival is 50% in Stage IA, 43% in 
Stage IB, 36% in Stage IIA, 25% in Stage IIB, 19% in Stage IIIA, 7% in Stage IIIB, and 2% in 
Stage IV. The median survival time is 14 months in Stage III and 10 months in Stage 
IV.(Goldstraw et al., 2007) 
In the period before the advent of HAART, HIV-infected patients were considered to have 
decreased immune competence of lymphocytes or CD4 cell counts because of accompanying 
complications or fragility to treatment. Toxicity and tolerance data in the treatment of other 
cancers are available. No fewer than 25% of advanced cancer patients with HIV infection 
were not treated,(Achenbach et al.) and among NSCLC patients with HIV infection, initial 
treatment consisted of chemotherapy in 31%, radiotherapy in 23%, and both in 15%.(D'Jaen 
et al., 2010) 
5.1 Surgery 
Surgery is a promising modality of treatment for Stage I and II NSCLC, and is the first-line 
choice of treatment for all operable patients. In previous reports, patients with CD4 cell 
counts of more than 500 cells/µL were considered operable, while in those with lower CD4 
cell counts, the indication for surgery needed careful consideration. The treatment of HIV-
infected lung cancer patients at present, however, should follow the standard of care for 
safety and efficacy, as their prognosis depends on their lung cancer, not their HIV status. 
Moreover, complications, such as cardiovascular diseases and interstitial pneumonia 
associated with cigarette smoking, need to be taken into account, because more of these 
patients have a history of smoking.(Aberg, 2009) 
With surgery, a reported case series did not demonstrate an increased risk of postoperative 
complications because of CD4 cell counts or immunological status.(Massera et al., 2000) 
Thus, the indication for surgery in HIV-infected lung cancer patients should be determined 
based on pulmonary function, PS, and staging, as in the general population. Furthermore, 
the prognosis of such patients is good.(Spano et al., 2004) In addition, the clinician should 
consider the medical staff’s perioperative risk for blood-borne infection and ensure that 
standard precautions are taken. The reported blood-borne infection rate associated with 
surgery ranges from 0.2-0.5%.(Bell, 1997) 
In determining the clinical stage, 18F-fluorodeoxyglucose-positoron emission tomography-
computed tomography (PET-CT) scan is a highly sensitive and specific examination. 
However, prudent assessment with regard to lymph nodal diagnosis is needed in the HIV 
population because of potential false positive to lymph nodes and upstaging in anal 
cancer.(Cotter et al., 2006) 
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With respect to adjuvant chemotherapy (postoperative chemotherapy) for patients with 
NSCLC, a 13% decrease in the risk of death was demonstrated with chemotherapy (HR 0.87, 
95%CI 0.74-1.02, p=0.08) in 1995.(Non-small Cell Lung Cancer Collaborative Group, 1995) 
This rate is equivalent to a 5% improvement in the 5-year survival rate. In later studies, a 5-
15% improvement in the 5-year survival rate was demonstrated (HR 0.89, 95%CI 0.82-0.96, 
p=0.005) in NSCLC patients with Stage II-IIIA with cisplatin-based chemotherapy.(Pignon et 
al., 2008) However, as described later, toxicity, efficacy and prognostic factors for HIV-
infected lung cancer patients are uncertain. 
5.2 Radiotherapy 
The role of radiotherapy in HIV-infected lung cancer patients is uncertain. In general, 
radiation therapy for ether ADCs or NADCs leads to severe mucosal toxicity in acute phase 
and late-phase disturbances, even when low-dose radiation is used. In KS patients who 
undergo thoracic irradiation, esophagitis occurs frequently and is often severe.(Chak et al., 
1988, Cooper et al., 1984) The mechanism of the more severe mucositis is considered to be 
related to decreased mucosal restoration due to a shortage of glutathione antioxidant(Buhl et 
al., 1989, Vallis, 1991) or to be related to OIs (Fungi, Candida species, herpes, 
cytomegalovirus, and Cryptococcus infections).(Boal et al., 1979, Rodriguez et al., 1989) 
In the patient with good PS or without weight loss, unresectable locoregionally advanced 
NSCLC or limited-disease SCLC, the standard of care is concurrent chemoradiotherapy. The 
3-year survival rate in unresectable locoregionally advanced NSCLC is around 10% with 
radiotherapy alone, and at present, the 3-year survival rate improves by more than 25% with 
concurrent platinum-based chemoradiotherapy.(Blackstock & Govindan, 2007) Concurrent 
chemoradiotherapy is more effective but more toxic than sequential chemoradiotherapy. At 
present, it is recommended that HIV-infected lung cancer patients be treated with the same 
standard care as the general population. However, aggressive treatment requires 
consideration of the risk of interactions between antiretroviral agents and antitumor agents, 
and fragility to treatment and safety of chemoradiotherapy are uncertain. A reported case 
having locally advanced squamous cell lung cancer, concurrently treated with nelfinavir 
and 5 species of HAART and intensity modulated radiotherapy, died of massive hemoptysis 
because of bronchial perforation, whereas pathological complete response (CR) was 
achieved with intensity modulated radiotherapy at a dose of 20 Gy.(Chapman et al., 2009) In 
a phase I study involving pancreatic cancer patients with HIV infection, a radiosensitizing 
effect with nelfinavir was reported.(Brunner et al., 2008) 
Conformal radiotherapy is appropriate, as in the general population, because of narrowing of 
the irradiation fields. Palliative radiotherapy is indicated according to symptoms in Stage IV. 
5.3 Chemotherapy 
With regard to chemotherapy, adjuvant chemotherapy is used for Stage IB-IIIA NSCLC, 
concomitant chemoradiotherapy is given in locoregionally advanced NSCLC, and palliative 
chemotherapy is given in Stage IV.(Azzoli et al., 2009) In the meta-analysis of Stage IV NSCLC, 
which accounts for 40% of all lung cancer, platinum doublet chemotherapy prolonged the 
median survival to 1.5-2.8 months and improved the 1-year survival rate to 10%.(Non-small 
Cell Lung Cancer Collaborative Group, 2008, Grilli et al., 1993, Marino et al., 1994, Souquet et 
al., 1993) Chemotherapy significantly improved survival, with a HR of 0.73 (p<0.0001) in 
1995.(Kivisto et al., 1995) In 2008, the same group reported the results of a meta-analysis of 16 
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randomized studies, and chemotherapy showed a survival benefit with an HR of 0.73 (95% CI 
0.71-0.83, p < 0.0001) again. On the other hand, the survival benefit is no different between 
1995 and later studies (p = 0.77) (Non-small Cell Lung Cancer Collaborative Group, 2008). 
However, the survival time has gradually improved because of trials with novel antitumor 
drugs that were excluded from this meta-analysis and diversification of treatment strategies. 
As the population with HIV infection is excluded from clinical trials, information regarding 
the efficacy and safety of chemotherapy in these patients is limited to retrospective reports. 
5.3.1 Chemotherapy for metastatic stage in patients with HIV infection 
5.3.1.1 Front-line setting 
Chemotherapy is more frequently used for advanced lung cancer in HIV-infected patients 
because 75-90% of lung cancer patients with HIV infection have advanced disease.(Lavole et 
al., 2006, Lavole et al., 2009, Cadranel et al., 2006) However, the benefit of chemotherapy is 
questionable, as the prospective clinical benefits and toxicities have not been realistically 
evaluated. In a phase II prospective study with carboplatin and gemcitabine combination 
chemotherapy followed by paclitaxel maintenance therapy involving 47 patients consisting 
mainly of lung cancer patients with poor PS (2 or 3) and immunologically fragile patients, 
including HIV infection and post-bone marrow transplantation, tolerance and efficacy were 
demonstrated to be adequate.(Bridges et al., 2008) Previous reports have concluded that the 
benefit of chemotherapy was controversial, but the prognosis of NSCLC patients with HIV 
infection treated with chemotherapy was reported to be the same as the prognosis of the 
general population with NSCLC. D’Jean et al. reported that, among HIV-infected lung 
cancer patients, 81% (taxanes 45%, gemcitabine 26%, vinca alkaloid 10%) were treated with 
platinum-doublet chemotherapy in the front-line setting. Patients treated with singlet 
chemotherapy or oral antitumor agents outside of standard regimens were 3% 
each.(Previous study, 2010) Elderly lung cancer patients and lung cancer patients with poor 
PS in the general population have a poorer prognosis with chemotherapy and singlet 
chemotherapy, not platinum-doublet chemotherapy, is generally recommended.(D'Addario 
et al., 2009) Among lung cancer patients with HIV infection, PS is poor (before 1996, 37~57% 
of patients had PS of more than 2; after 1996, this decreased to less than 30% of 
patients)(Spano et al., 2004) Thus, for treatment of fragile patients, chemotherapy would be 
applied to lung cancer patients with HIV infection. 
Current standard chemotherapy for advanced NSCLC is based on platinum doublet 
(cisplatin or carboplatin) plus third-generation antitumor drugs (irinotecan, docetaxel, 
gemcitabine, vinorelbine, paclitaxel,(Schiller et al., 2002, Kelly et al., 2001, Ohe et al., 2007) 
and pemetrexed(Scagliotti et al., 2008)) or EGFR-TKIs; gefitinib(Maemondo et al., 2010, 
Mitsudomi et al., 2009) and erlotinib(Rosell et al., 2009), and an antiangiogenic inhibitor 
(bevacizumab).(Sandler et al., 2006) Maintenance therapy with pemetrexed(Ciuleanu et al., 
2009) and erlotinib(Cappuzzo et al., 2010) is known to prolong survival. In SCLC, platinum 
and etoposide or irinotecan combination therapy is used.(Murray & Turrisi, 2006) For 
relapsed SCLC, amrubicin or topotecan is given. In locally advanced NSCLC and limited 
disease (LD) SCLC, thoracic irradiation is added. D’Jean et al. reported that, among HIV-
infected lung cancer patients, the agents combined with platinum agents were 
topoisomerase in 67%, vinca alkaloid in 22%, and taxanes in 11%. The response rate to front-
line chemotherapy was 39% in 41 patients. Of the treated patients, 63% had adverse events, 
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and 34% were Grade 3/4. Treatment-related deaths were seen in 2 patients (0.05%); 1 with 
pneumonitis, and 1 from an unknown cause.(Previous study, 2010) 
5.3.1.2 Second-line setting 
Overall, 60% of lung cancer patients treated with front-line chemotherapy proceed to 
second-line chemotherapy. In NSCLC patients with good PS, the standard of care is 
docetaxel (Shepherd et al., 2001, Fossella et al., 2000), pemetrexed(Hanna et al., 2004) and 
erlotinib.(Shepherd et al., 2005) Docetaxel is indicated for all histological types of NSCLC. 
Pemetrexed is expected to be active for non-squamous cell histology.(Scagliotti et al., 2009) 
Erlotinib is effective for both patients harboring EGFR mutation and EGFR wild-
type,(Ciuleanu et al., 2010) although the response rate and survival time differ between 
them. Platinum doublet chemotherapy or non-platinum doublet chemotherapy is not 
anticipated to have efficacy in the second-line setting.(Azzoli et al., 2009) For SCLC, 
intravenous or oral topotecan,(Eckardt et al., 2007, von Pawel et al., 1999) amrubicin,(Inoue et 
al., 2008, Onoda et al., 2006) and carboplatin and paclitaxel, re-treatment for sensitive-relapse 
cases are considered.(Giaccone et al., 1987, Postmus et al., 1987, Groen et al., 1999) In the HIV 
population, details concerning second-line chemotherapy in Stage IV are uncertain. The 
rates of HIV-infected lung cancer patients treated with second-line chemotherapy in HIV 
population were 32% (17/53) in NSCLC and 10% (1/9) in SCLC. The response rate in this 
study was 11%, as in the general population.(D'Jaen et al., 2010) 
5.3.1.3 Molecular targeted agents 
The understanding of cancer at the molecular level is profound, and proteins playing 
significant roles in tumor proliferation, invasion, and metastasis have been identified. As a 
result, molecular targeted inhibitors or antibodies for these proteins have recently been 
developed. Of these, drugs targeting EGFR, vascular endothelial growth factor (VEGF), and 
echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase 
translocation (EML4-ALK)(Kwak et al., 2010) have been shown to be efficacious. EGFR-
targeted drugs have particularly strong evidence supporting their use. In NSCLC harboring 
EGFR mutation in the general population, use of EGFR-TKIs doubles survival.(Mitsudomi et 
al., 2009, Maemondo et al., 2010, Rosell et al., 2009) Thus, despite the potential for drug 
interactions, use of EGFR-TKIs is indicated in HIV-infected patients. Though no drug 
interactions are expected, prudence is required from the perspective of cost and safety. 
5.3.2 Pharmacodynamic interactions between HAART & cytotoxic antitumor agents 
HAART reconstructs immunity and decreases risk of OIs to inhibit HIV viral load and 
increase CD4 cell counts for patients infected with HIV. The goal for HAART is to 
continuously suppress the viral load to undetectable and maintain CD4 cell counts above 
500 cells/µL.(Silverberg et al., 2007) However, decreases in antiretroviral agent 
concentrations can exacerbate clinical status, and increased/decreased concentrations of 
antitumor agents lead to severe toxicity or reduced antitumor effects. Both increases and 
decreases in serum concentrations can occur for either/both antiretroviral agents and/or 
cytotoxic antitumor agents.(Kivisto et al., 1995) Therefore, decreased effectiveness and 
increased toxicity of chemotherapy must be considered. In addition, failure of virological 
treatment may occur. Interactions between antiretroviral agents and chemotherapeutic 
agents must always be considered and are a cause for concern for oncologists in clinical 
settings.  
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Expected chemotherapeutic concentration 
modifications based on antiretroviral drugs used
Expected interactions between 
HAART and chemotherapy 
NRTI NNRTI PI INSTI FI MVC
Platinum ń ń ń ń ń ń Hematological toxicity with ZDV, 
Neuropathy, Nephropathy with TDF 
Taxanes ń Ņ Ń ń ń ń Hematological toxicity with ZDV 
Neuropathy with d4T and DDI 
Etoposide ń Ņ Ń ń ń ń Hematological toxicity with ZDV 
Gemcitabine ń ń ń ń ń ń Hematological toxicity with ZDV 
Nephropathy with TDF 
Pemetrexed ń ń ń ń ń ń Hematological toxicity with ZDV 
Topotecan ń ń ń ń ń ń Hematological toxicity with ZDV 
Irinotecan ń Ņ Ń ń ń ń Hematological toxicity with ZDV 
Gefitinib 
Erlotinib 
ń Ņ Ń ń ń ń None 
Bevacizumab ń ń ń ń ń ń None 
INSTI: integrase strand transfar inhibitor; FI: fusion inhibitor; MVC: maraviroc; ZDV: zidovudine;  
TDF: tenofovir; ddI: didanosine 
Table 3. Expected drug interactions between antiretroviral agents and antitumor agents 
commonly used in NSCLC and SCLC.(Makinson et al., 2010) 
However, the available pharmacokinetic data for antiretroviral drugs and antitumor agents 
are not predictive: 1. available pharmacokinetic data are limited to case reports, and limited 
individual data cannot be generalized; 2. antitumor agents of a similar class can have 
variable pharmacokinetics; and 3. unexpected drug interactions can occur because 
metabolism by CYP450 is associated with single nucleotide polymorphisms (SNPs). 
Antiretroviral agents are classified into six categories: nucleoside reverse transcriptase 
inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease 
inhibitors (PIs); integrase inhibitors; fusion inhibitor enfuvirtide; and C-C chemokine 
receptor type 5 (CCR5) coreceptor antagonists. Interactions among these during treatment 
for ADCs, such as PCNSL or KS, enhance adverse toxicities. For instance, KS patients with 
CD4 cell counts greater than 200 cells/µL are reported to have a good response to paclitaxel 
treatment, with the same prognosis as patients with a normal immunological status. 
Drug interaction between antiretroviral agents and antitumor agents is assumed when the 
drug is metabolized by CYP450 pathway. Many PIs and NNRTIs are metabolized by this 
pathway, and competitive metabolism between antitumor drugs must be considered. (Table 3) 
Increases in toxicity between antiretroviral agents and antitumor agents have been reported. 
Among NNRTIs, efavirenz increases toxicity with concomitant use of vinka alkaloids and 
taxanes.(Makinson et al., 2010) All NRTIs and most PIs have increased drug sensitivities in vitro, 
and this leads to increased toxicity. The NRTIs efavirenz, delavirdine, and nevirapine are 
primarily metabolized by CYP450.(Gulick, 1998, Flexner, 1998) In a study of patients with NHL 
undergoing treatment with concomitant antiretroviral agents and cyclophosphamide, 
doxorubicin, and etoposide, significantly lower nadir neutrophil counts were seen. As 
compared to the group with/without PIs, the group with PIs had greater toxicity (48% vs. 27%; 
p=0.0025). Drug interactions have also been confirmed in vitro; cultured cells that expressed P-
glycoprotein (P-gp) accumulated increased concentrations of paclitaxel or vinblastine 
concomitant with PIs.(Washington et al., 1998) PIs such as ritonavir and indinavir have a strong 
affinity for CYP450 and also strongly inhibit CYP3A4. These enzymes are used in metabolic 
pathways with ifosfamide, docetaxel, paclitaxel, irinotecan, vinca alkaloids, and 
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etoposide.(Rowinsky & Donehower, 1997, Stebbing & Bower, 2006) Severe myelosuppression 
with atazanavir(Richman et al., 1987, Tan & Ratner, 1997) and peripheral neuropathy with 
didanosine, stavudine, and zalcitabine occur.(Rowinsky & Donehower, 1997) Thus, their 
combined use with platinum or paclitaxel leads to increased toxicities. Combination treatment 
with irinotecan and atazanavir is also contraindicated. Cisplatin, the key drug in lung cancer 
chemotherapy,(Azzoli et al., 2009, Barlesi & Pujol, 2005) is not metabolized by the CYP450 
enzyme pathway. Thus, drug interactions with HAART do not occur, but accumulating 
toxicity, such as nephrotoxicity and neurotoxicity, must be considered. In addition, patients on 
antiretroviral agents having nephrotoxicity such as tenofovir disoproxil require careful follow-
up. 
Of the molecular targeted agents, EGFR-TKIs have been poorly evaluated, but they are 
known to be metabolized by CYP3A4, and ritonavir should be avoided. Raltegravir is 
metabolized by UGT1A1 (uridine diphosphate glucuronosyl transferase isoform 1) and does 
not induce or inhibit hepatic enzymes; thus, drug interactions appear to be absent. 
Maraviroc, a CCR5 antagonist, also does not interact with CYP3A4. As for PIs, indinavir and 
sequinavir inhibit cell proliferation or invasion by acting through matrix 
metalloprotease.(Toschi et al., 2011) Due to the increased toxicity of such drug interactions, 
the drugs that are better to apply in HAART regimens with antiretroviral drug are those not 
associated with CYP450, such as NRTI, raltegravir, or enfuvirtide. 
In the future, dose adjustments will be used to investigate Pharmacokinetic data via a 
prospective study; however, the prognosis of lung cancer patients with HIV infection is 
anticipated to be similar to that in the general population. Thus, conventional doses and 
regimens are adequate.  
5.3.3 Prevention of opportunistic infections & potential complications 
An increased risk of OIs is considered to be a complication of chemotherapy because of the 
associated decrease in CD4 cell counts. In lung cancer patients, changes in CD4 cell counts 
with chemotherapy are unclear. However, previous reports on treatment for ADCs provide 
information about changes in CD4 cell counts. CD4 cell counts in NHL on chemotherapy 
decreased to 50% of baseline at the nadir and recovered within a month. CD4 cell counts and 
viral load do not change with chemotherapeutic treatment.(Powles et al., 2002) In addition, in 
ADCs, CD4 cell counts in patients receiving concomitant HAART or HIV viral load-negative 
patients are considered to recover sooner.(Powles et al., 2002, Hakim et al., 1997) OIs on 
chemotherapy occurred in 8 of 25 patients (32%), and their CD4 cell counts were less than 150 
cells/µL. These patients also had poor PS, and half of the patients developed Grade 3 or 4 
hematological toxicity.(Tirelli et al., 2000) Recent few reports have discussed the occurrence of 
OIs during chemotherapy. Primary prevention of OIs is adequate; no specific preventive 
therapies are necessary in patients with a well-controlled viral load. Generally, in patients with 
less than 200 cells/µL, trimethoprim-sulfamethoxazole or pentamidine inhalation is used for 
pneumocystis pneumonia prevention, and in patients with less than 50 cells/µL, a macrolide is 
used for Mycobacteriaum avium complex (MAC) prevention. Thus, a monthly CD4 cell count 
check is preferred during chemotherapy and one month after treatment. 
5.4 Supportive care 
In supportive care, drug interactions between antiretroviral agents and other agents must be 
considered (Table 4). However, in clinical settings, physicians must administer palliative 
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therapy. Interactions between morphine and some HAART drugs have been shown, but the 
benefit of morphine for palliation remains. In Stage IV NSCLC, early induction of palliative 
therapy after diagnosis significantly improves quality of life and mood, and prolongs survival 
by 2 months.(Temel et al., 2010) As in patients from the general population, early palliative 
therapy is indicated for HIV-infected patients, as well as psychological support at the end-stage. 
As for the lung cancer patients with bone metastasis, zoledronic acid, a new 
bisphosphonate, is an appropriate palliative treatment for skeletal-related events (SREs) and 
symptoms associated with bone metastases.(Rosen et al., 2003a, Rosen et al., 2003b) The 
efficacy and safety of zoledronic acid given concomitantly with HAART for the osteoporosis 
that is associated with long-term HAART administration have been evaluated in a clinical 
trial and found to be advantageous.(Bolland et al., 2008, Bolland et al., 2007, Huang et al., 
2009) When SREs occur, they are associated with decreased activities of daily living and 
shorter survival.(Tsuya et al., 2007) Thus, zoledronic acid should be given to patients with 
bone metastases of lung cancer, even asymptomatic. 
 
 
Expected concentration modifications in drugs used supportive care 
based on antiretroviral drugs used 
NRTI NNRTI PI INSTI FI MVC 
Dexamethasone ń Ņ Ņ ń ń ń 
Lorazepam ń Ņ Ń ń ń ń 
Tricyclic 
antidepressants 
ń ń Ń ń ń ń 
Fentanyl ń ń Ń ń ń ń 
Carbamazepine ń Ņ Ņ ń ń ń 
Table 4. Expected drug interactions between antiretroviral agents and frequently used 
supportive agents for chemotherapy. 
6. Prognosis 
Lung cancer patients with HIV infections are considered to have a poorer prognosis than the 
general population because of their younger age, immunodeficiency, aggressive extension, and 
more advanced stage at diagnosis. In a meta-analysis, the median survival time was 5-9 
months.(Powles et al., 2003, Karp et al., 1993, Sridhar et al., 1992, Tirelli et al., 2000, Spano et al., 
2004, Alshafie et al., 1997) The 1-year survival of HIV-infected lung cancer patients was 10% (0-
15%), as compared to 40% (20-50%) in the general population.(Cadranel et al., 2006, Cinti et al., 
2008, Grubb et al., 2006, Vyzula & Remick, 1996) Over the last 20 years, survival by histology 
was about 7 months in SCLC and 5 months in NSCLC.(Hakimian et al., 2007) Favorable 
prognostic factors are reported to be good PS and early stage at diagnosis. The concomitant use 
of HAART is controversial as a prognostic factor. The reason for these patients’ poor prognosis 
is considered to be their more advanced stage at diagnosis.(Lavole et al., 2009) 
CD4 cell count is sometimes considered to be a prognostic factor for chemotherapy. The 
prognosis for patients with a CD4 cell count greater than 200 cells/µL is 11.5 months, while 
that for patients with a CD4 cell count less than 200 cells/µL is 3.4 months.(Hakimian et al., 
2007) At present, patients with CD4 cell counts greater than 200 cells/µL can be given 
chemotherapy, and they have been demonstrated to have the comparable survival to non-
HIV patients. (Hakimian et al., 2007) 
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7. Future directions 
Lung cancer has become common in HIV-infected patients and appears to be increasing in 
clinical settings, and NADCs have become the main cause of death. Thus, lung cancer has 
significant clinical meaning in the management of HIV-infected patients. Knowledge about 
its epidemiology, screening, risk factors, and intervention will reduce the incidence of lung 
cancer. In particular, aggressively promoting smoking cessation programs and screening for 
lung cancer for earlier detection will play important roles as strategies in preventing lung 
cancer. 
HIV-infected patients should receive standard care for lung cancer, and it is anticipated that 
they will have the same prognosis as the general population. However, for these patients, 
we need to consider previously reported toxicities and fragility to treatment. In addition, 
increased intensity of treatment due to drug interactions and increased radiosensitization 
with HAART must be considered. As the clinical details of such patients have not been well 
reported, infectious disease physicians and oncologists must collaborate when treating HIV-
infected lung cancer patients. 
8. References 
Aberg, J.A. (2009). Cardiovascular complications in HIV management: past, present, and 
future. J Acquir Immune Defic Syndr, Vol.50, No.1, pp. 54-64 
Aberle, D.R., Berg, C.D., Black, W.C. et al. (2010). The National Lung Screening Trial: 
overview and study design. Radiology, Vol.258, No.1, pp. 243-253 
Achenbach, C.J., Cole, S.R., Kitahata, M.M. et al. Mortality after cancer diagnosis in HIV-
infected individuals treated with antiretroviral therapy. AIDS, pp.  
Agostini, C., Sancetta, R., Cerutti, A. et al. (1995). Alveolar macrophages as a cell source of 
cytokine hyperproduction in HIV-related interstitial lung disease. J Leukoc Biol, 
Vol.58, No.5, pp. 495-500 
Allard, J.P., Aghdassi, E., Chau, J. et al. (1998). Oxidative stress and plasma antioxidant 
micronutrients in humans with HIV infection. Am J Clin Nutr, Vol.67, No.1, pp. 143-
147 
Alshafie, M.T., Donaldson, B. & Oluwole, S.F. (1997). Human immunodeficiency virus and 
lung cancer. Br J Surg, Vol.84, No.8, pp. 1068-1071 
Azzoli, C.G., Baker, S., Jr., Temin, S. et al. (2009). American Society of Clinical Oncology 
Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell 
lung cancer. J Clin Oncol, Vol.27, No.36, pp. 6251-6266 
Baker, M.E., Yan, L. & Pear, M.R. (2000). Three-dimensional model of human TIP30, a 
coactivator for HIV-1 Tat-activated transcription, and CC3, a protein associated 
with metastasis suppression. Cell Mol Life Sci, Vol.57, No.5, pp. 851-858 
Barlesi, F. & Pujol, J.L. (2005). Combination of chemotherapy without platinum compounds 
in the treatment of advanced non-small cell lung cancer: a systematic review of 
phase III trials. Lung Cancer, Vol.49, No.3, pp. 289-298 
Bedimo, R.J., Mcginnis, K.A., Dunlap, M. et al. (2009). Incidence of non-AIDS-defining 
malignancies in HIV-infected versus noninfected patients in the HAART era: 
impact of immunosuppression. J Acquir Immune Defic Syndr, Vol.52, No.2, pp. 203-
208 
www.intechopen.com
 HIV and Lung Cancer   
 
407 
Bell, D.M. (1997). Occupational risk of human immunodeficiency virus infection in 
healthcare workers: an overview. Am J Med, Vol.102, No.5B, pp. 9-15 
Benard, A., Bonnet, F., Tessier, J.F. et al. (2007). Tobacco addiction and HIV infection: toward 
the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS 
Patient Care STDS, Vol.21, No.7, pp. 458-468 
Bertolaccini, L., Lybéris, P., Soncini, S. et al. (2008). Clinical characteristic lung cancer in 
HIV-infected patients. Cancer Therapy, Vol.6, pp. 903-906 
Blackstock, A.W. & Govindan, R. (2007). Definitive chemoradiation for the treatment of 
locally advanced non small-cell lung cancer. J Clin Oncol, Vol.25, No.26, pp. 4146-
4152 
Boal, D.K., Newburger, P.E. & Teele, R.L. (1979). Esophagitis induced by combined radiation 
and adriamycin. AJR Am J Roentgenol, Vol.132, No.4, pp. 567-570 
Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2008). Effects of intravenous zoledronate on 
bone turnover and BMD persist for at least 24 months. J Bone Miner Res, Vol.23, 
No.8, pp. 1304-1308 
Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2007). Annual zoledronate increases bone 
density in highly active antiretroviral therapy-treated human immunodeficiency 
virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab, Vol.92, 
No.4, pp. 1283-1288 
Bonnet, F., Burty, C., Lewden, C. et al. (2009). Changes in cancer mortality among HIV-
infected patients: the Mortalite 2005 Survey. Clin Infect Dis, Vol.48, No.5, pp. 633-
639 
Bower, M., Powles, T., Nelson, M. et al. (2003). HIV-related lung cancer in the era of highly 
active antiretroviral therapy. AIDS, Vol.17, No.3, pp. 371-375 
Bridges, B.B., Thomas, L., Hausner, P.F. et al. (2008). Phase II trial of 
gemcitabine/carboplatin followed by paclitaxel in patients with performance 
status=2,3 or other significant co-morbidity (HIV infection or s/p organ 
transplantation) in advanced non-small cell lung cancer. Lung Cancer, Vol.61, No.1, 
pp. 61-66 
Brock, M.V., Hooker, C.M., Engels, E.A. et al. (2006). Delayed diagnosis and elevated 
mortality in an urban population with HIV and lung cancer: implications for 
patient care. J Acquir Immune Defic Syndr, Vol.43, No.1, pp. 47-55 
Brunner, T.B., Geiger, M., Grabenbauer, G.G. et al. (2008). Phase I trial of the human 
immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for 
locally advanced pancreatic cancer. J Clin Oncol, Vol.26, No.16, pp. 2699-2706 
Bruyand, M., Thiebaut, R., Lawson-Ayayi, S. et al. (2009). Role of uncontrolled HIV RNA 
level and immunodeficiency in the occurrence of malignancy in HIV-infected 
patients during the combination antiretroviral therapy era: Agence Nationale de 
Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis, Vol.49, No.7, 
pp. 1109-1116 
Buhl, R., Jaffe, H.A., Holroyd, K.J. et al. (1989). Systemic glutathione deficiency in symptom-
free HIV-seropositive individuals. Lancet, Vol.2, No.8675, pp. 1294-1298 
Cadranel, J., Garfield, D., Lavole, A. et al. (2006). Lung cancer in HIV infected patients: facts, 
questions and challenges. Thorax, Vol.61, No.11, pp. 1000-1008 
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
408 
Cappuzzo, F., Ciuleanu, T., Stelmakh, L. et al. (2010). Erlotinib as maintenance treatment in 
advanced non-small-cell lung cancer: a multicentre, randomised, placebo-
controlled phase 3 study. Lancet Oncol, Vol.11, No.6, pp. 521-529 
Chak, L.Y., Gill, P.S., Levine, A.M. et al. (1988). Radiation therapy for acquired 
immunodeficiency syndrome-related Kaposi's sarcoma. J Clin Oncol, Vol.6, No.5, 
pp. 863-867 
Chapman, C.H., Shen, J., Filion, E.J. et al. (2009). Marked tumor response and fatal 
hemoptysis during radiation for lung cancer in a human immunodeficiency virus-
positive patient taking nelfinavir. J Thorac Oncol, Vol.4, No.12, pp. 1587-1589 
Cinti, S.K., Gandhi, T. & Riddell, J.T. (2008). Non-AIDS-defining cancers: should 
antiretroviral therapy be initiated earlier? AIDS Read, Vol.18, No.1, pp. 18-20, 26-32 
Ciuleanu, T., Brodowicz, T., Zielinski, C. et al. (2009). Maintenance pemetrexed plus best 
supportive care versus placebo plus best supportive care for non-small-cell lung 
cancer: a randomised, double-blind, phase 3 study. Lancet, Vol.374, No.9699, pp. 
1432-1440 
Ciuleanu, T., Stelmakh, L., Cicenas, S. et al. (2010). LBOA5 - Erlotinib versus docetaxel or 
pemetrexed as second-line therapy in patients with advanced non-small-cell lung 
cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III 
TITAN study. 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, 
Vol.Abstract, pp.  
Clifford, G. & Franceschi, S. (2007). Immunity, infection, and cancer. Lancet, Vol.370, 
No.9581, pp. 6-7 
Cooper, J.S., Fried, P.R. & Laubenstein, L.J. (1984). Initial observations of the effect of 
radiotherapy on epidemic Kaposi's sarcoma. JAMA, Vol.252, No.7, pp. 934-935 
Cotter, S.E., Grigsby, P.W., Siegel, B.A. et al. (2006). FDG-PET/CT in the evaluation of anal 
carcinoma. Int J Radiat Oncol Biol Phys, Vol.65, No.3, pp. 720-725 
Crum-Cianflone, N., Hullsiek, K.H., Marconi, V. et al. (2009). Trends in the incidence of 
cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-
year cohort study. AIDS, Vol.23, No.1, pp. 41-50 
D'addario, G., Fruh, M., Reck, M. et al. Metastatic non-small-cell lung cancer: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, Vol.21 
Suppl 5, pp. v116-119 
D'arminio Monforte, A., Cinque, P., Mocroft, A. et al. (2004). Changing incidence of central 
nervous system diseases in the EuroSIDA cohort. Ann Neurol, Vol.55, No.3, pp. 320-
328 
D'jaen, G.A., Pantanowitz, L., Bower, M. et al. (2010). Human immunodeficiency virus-
associated primary lung cancer in the era of highly active antiretroviral therapy: a 
multi-institutional collaboration. Clin Lung Cancer, Vol.11, No.6, pp. 396-404 
Eckardt, J.R., Von Pawel, J., Pujol, J.L. et al. (2007). Phase III study of oral compared with 
intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol, 
Vol.25, No.15, pp. 2086-2092 
El Maalouf, G., Rodier, J.M., Faivre, S. et al. (2007). Could we expect to improve survival in 
small cell lung cancer? Lung Cancer, Vol.57 Suppl 2, pp. S30-34 
Engels, E.A., Biggar, R.J., Hall, H.I. et al. (2008). Cancer risk in people infected with human 
immunodeficiency virus in the United States. Int J Cancer, Vol.123, No.1, pp. 187-
194 
www.intechopen.com
 HIV and Lung Cancer   
 
409 
Engels, E.A., Brock, M.V., Chen, J. et al. (2006). Elevated incidence of lung cancer among 
HIV-infected individuals. J Clin Oncol, Vol.24, No.9, pp. 1383-1388 
Erickson, T.M., Koeppe, J.R., Miller, Y.E. et al. (2008). Bronchioloalveolar carcinoma 
presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a 
diagnosis worth making. J Thorac Oncol, Vol.3, No.11, pp. 1353-1355 
Flexner, C. (1998). HIV-protease inhibitors. N Engl J Med, Vol.338, No.18, pp. 1281-1292 
Fossella, F.V., Devore, R., Kerr, R.N. et al. (2000). Randomized phase III trial of docetaxel 
versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung 
cancer previously treated with platinum-containing chemotherapy regimens. The 
TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, Vol.18, No.12, pp. 
2354-2362 
Friis-Moller, N., Weber, R., Reiss, P. et al. (2003). Cardiovascular disease risk factors in HIV 
patients--association with antiretroviral therapy. Results from the DAD study. 
AIDS, Vol.17, No.8, pp. 1179-1193 
Frisch, M., Biggar, R.J., Engels, E.A. et al. (2001). Association of cancer with AIDS-related 
immunosuppression in adults. JAMA, Vol.285, No.13, pp. 1736-1745 
Frisch, M. & Hjalgrim, H. (1999). Re: Nonmelanomatous skin cancer following cervical, 
vaginal, and vulvar neoplasms: etiologic association. J Natl Cancer Inst, Vol.91, 
No.6, pp. 565-566 
Giaccone, G., Ferrati, P., Donadio, M. et al. (1987). Reinduction chemotherapy in small cell 
lung cancer. Eur J Cancer Clin Oncol, Vol.23, No.11, pp. 1697-1699 
Goldstraw, P., Crowley, J., Chansky, K. et al. (2007). The IASLC Lung Cancer Staging 
Project: proposals for the revision of the TNM stage groupings in the forthcoming 
(seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 
Vol.2, No.8, pp. 706-714 
Gordon, S.B., Janoff, E.N., Sloper, D. et al. (2005). HIV-1 infection is associated with altered 
innate pulmonary immunity. J Infect Dis, Vol.192, No.8, pp. 1412-1416 
Grilli, R., Oxman, A.D. & Julian, J.A. (1993). Chemotherapy for advanced non-small-cell 
lung cancer: how much benefit is enough? J Clin Oncol, Vol.11, No.10, pp. 1866-1872 
Groen, H.J., Fokkema, E., Biesma, B. et al. (1999). Paclitaxel and carboplatin in the treatment 
of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and 
etoposide: a non-cross-resistant schedule. J Clin Oncol, Vol.17, No.3, pp. 927-932 
Grubb, J.R., Moorman, A.C., Baker, R.K. et al. (2006). The changing spectrum of pulmonary 
disease in patients with HIV infection on antiretroviral therapy. AIDS, Vol.20, No.8, 
pp. 1095-1107 
Grulich, A.E., Van Leeuwen, M.T., Falster, M.O. et al. (2007). Incidence of cancers in people 
with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-
analysis. Lancet, Vol.370, No.9581, pp. 59-67 
Gulick, R. (1998). Combination therapy for patients with HIV-1 infection: the use of dual 
nucleoside analogues with protease inhibitors and other agents. AIDS, Vol.12 Suppl 
3, pp. S17-22 
Hakim, F.T., Cepeda, R., Kaimei, S. et al. (1997). Constraints on CD4 recovery 
postchemotherapy in adults: thymic insufficiency and apoptotic decline of 
expanded peripheral CD4 cells. Blood, Vol.90, No.9, pp. 3789-3798 
Hakimian, R., Fang, H., Thomas, L. et al. (2007). Lung cancer in HIV-infected patients in the 
era of highly active antiretroviral therapy. J Thorac Oncol, Vol.2, No.4, pp. 268-272 
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
410 
Hanna, N., Shepherd, F.A., Fossella, F.V. et al. (2004). Randomized phase III trial of 
pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously 
treated with chemotherapy. J Clin Oncol, Vol.22, No.9, pp. 1589-1597 
Herida, M., Mary-Krause, M., Kaphan, R. et al. (2003). Incidence of non-AIDS-defining 
cancers before and during the highly active antiretroviral therapy era in a cohort of 
human immunodeficiency virus-infected patients. J Clin Oncol, Vol.21, No.18, pp. 
3447-3453 
Hodgson, D.M., Yirmiya, R., Chiappelli, F. et al. (1998). Intracerebral HIV glycoprotein 
(gp120) enhances tumor metastasis via centrally released interleukin-1. Brain Res, 
Vol.781, No.1-2, pp. 244-251 
Huang, J., Meixner, L., Fernandez, S. et al. (2009). A double-blinded, randomized controlled 
trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS, 
Vol.23, No.1, pp. 51-57 
Inoue, A., Sugawara, S., Yamazaki, K. et al. (2008). Randomized phase II trial comparing 
amrubicin with topotecan in patients with previously treated small-cell lung 
cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol, Vol.26, 
No.33, pp. 5401-5406 
Irwin, L.E., Begandy, M.K. & Moore, T.M. (1984). Adenosquamous carcinoma of the lung 
and the acquired immunodeficiency syndrome. Ann Intern Med, Vol.100, No.1, pp. 
158 
James, J.S. (2006). Lung cancer: very high death rate with HIV, huge reduction possible with 
CT screening for early diagnosis. AIDS Treat News, No.420, pp. 5-6 
Karp, J., Profeta, G., Marantz, P.R. et al. (1993). Lung cancer in patients with 
immunodeficiency syndrome. Chest, Vol.103, No.2, pp. 410-413 
Kelly, K., Crowley, J., Bunn, P.A., Jr. et al. (2001). Randomized phase III trial of paclitaxel 
plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with 
advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin 
Oncol, Vol.19, No.13, pp. 3210-3218 
Kirk, G.D., Merlo, C., P, O.D. et al. (2007). HIV infection is associated with an increased risk 
for lung cancer, independent of smoking. Clin Infect Dis, Vol.45, No.1, pp. 103-110 
Kivisto, K.T., Kroemer, H.K. & Eichelbaum, M. (1995). The role of human cytochrome P450 
enzymes in the metabolism of anticancer agents: implications for drug interactions. 
Br J Clin Pharmacol, Vol.40, No.6, pp. 523-530 
Kwak, E.L., Bang, Y.J., Camidge, D.R. et al. (2010). Anaplastic lymphoma kinase inhibition in 
non-small-cell lung cancer. N Engl J Med, Vol.363, No.18, pp. 1693-1703 
Lavole, A., Chouaid, C., Baudrin, L. et al. (2009). Effect of highly active antiretroviral 
therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung 
Cancer, Vol.65, No.3, pp. 345-350 
Lavole, A., Wislez, M., Antoine, M. et al. (2006). Lung cancer, a new challenge in the HIV-
infected population. Lung Cancer, Vol.51, No.1, pp. 1-11 
Levine, A.M., Seaberg, E.C., Hessol, N.A. et al. (2010). HIV as a risk factor for lung cancer in 
women: data from the Women's Interagency HIV Study. J Clin Oncol, Vol.28, No.9, 
pp. 1514-1519 
Maemondo, M., Inoue, A., Kobayashi, K. et al. (2010). Gefitinib or chemotherapy for non-
small-cell lung cancer with mutated EGFR. N Engl J Med, Vol.362, No.25, pp. 2380-
2388 
www.intechopen.com
 HIV and Lung Cancer   
 
411 
Makinson, A., Pujol, J.L., Le Moing, V. et al. (2010). Interactions between cytotoxic 
chemotherapy and antiretroviral treatment in human immunodeficiency virus-
infected patients with lung cancer. J Thorac Oncol, Vol.5, No.4, pp. 562-571 
Marino, P., Pampallona, S., Preatoni, A. et al. (1994). Chemotherapy vs supportive care in 
advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. 
Chest, Vol.106, No.3, pp. 861-865 
Massera, F., Rocco, G., Rossi, G. et al. (2000). Pulmonary resection for lung cancer in HIV-
positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer, 
Vol.29, No.2, pp. 147-149 
Mitsudomi, T., Morita, S., Yatabe, Y. et al. (2009). Gefitinib versus cisplatin plus docetaxel in 
patients with non-small-cell lung cancer harbouring mutations of the epidermal 
growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. 
Lancet Oncol, Vol.11, No.2, pp. 121-128 
Murray, N. & Turrisi, A.T., 3rd (2006). A review of first-line treatment for small-cell lung 
cancer. J Thorac Oncol, Vol.1, No.3, pp. 270-278 
Nguyen, M.L., Farrell, K.J. & Gunthel, C.J. Non-AIDS-Defining Malignancies in Patients 
with HIV in the HAART Era. Curr Infect Dis Rep, Vol.12, No.1, pp. 46-55 
Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell 
lung cancer: a meta-analysis using updated data on individual patients from 52 
randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 
Vol.311, No.7010, pp. 899-909 
Non-small Cell Lung Cancer Collaborative Group (2008). Chemotherapy in addition to 
supportive care improves survival in advanced non-small-cell lung cancer: a 
systematic review and meta-analysis of individual patient data from 16 
randomized controlled trials. J Clin Oncol, Vol.26, No.28, pp. 4617-4625 
Ohe, Y., Ohashi, Y., Kubota, K. et al. (2007). Randomized phase III study of cisplatin plus 
irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and 
cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm 
Cooperative Study in Japan. Ann Oncol, Vol.18, No.2, pp. 317-323 
Okuma, Y., Hosomi, Y., Takagi, Y. et al. (2010). Long-term survival following metachronous 
intratumoral hemorrhage in an HIV-infected patient with lung cancer. Int J Clin 
Oncol, Vol.15, No.5, pp. 515-518 
Onoda, S., Masuda, N., Seto, T. et al. (2006). Phase II trial of amrubicin for treatment of 
refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group 
Study 0301. J Clin Oncol, Vol.24, No.34, pp. 5448-5453 
Pakkala, S., Chen, Z., Rimland, D. et al. (2010). HIV-associated lung cancer in the era of 
highly active antiretroviral therapy (HAART): Correlation between CD4 count and 
outcome. J Clin Oncol, Vol.28, No.15s, pp. suppl; abstr 7632 
Parker, M.S., Leveno, D.M., Campbell, T.J. et al. (1998). AIDS-related bronchogenic 
carcinoma: fact or fiction? Chest, Vol.113, No.1, pp. 154-161 
Patel, P., Hanson, D.L., Sullivan, P.S. et al. (2008). Incidence of types of cancer among HIV-
infected persons compared with the general population in the United States, 1992-
2003. Ann Intern Med, Vol.148, No.10, pp. 728-736 
Petoumenos, K., Hui, E., Kumarasamy, N. et al. (2010). Cancers in the TREAT Asia HIV 
Observational Database (TAHOD): a retrospective analysis of risk factors. J Int 
AIDS Soc, Vol.13, No.1, pp. 51 
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
412 
Pignon, J.P., Tribodet, H., Scagliotti, G.V. et al. (2008). Lung adjuvant cisplatin evaluation: a 
pooled analysis by the LACE Collaborative Group. J Clin Oncol, Vol.26, No.21, pp. 
3552-3559 
Postmus, P.E., Berendsen, H.H., Van Zandwijk, N. et al. (1987). Retreatment with the 
induction regimen in small cell lung cancer relapsing after an initial response to 
short term chemotherapy. Eur J Cancer Clin Oncol, Vol.23, No.9, pp. 1409-1411 
Powles, T., Imami, N., Nelson, M. et al. (2002). Effects of combination chemotherapy and 
highly active antiretroviral therapy on immune parameters in HIV-1 associated 
lymphoma. AIDS, Vol.16, No.4, pp. 531-536 
Powles, T., Robinson, D., Stebbing, J. et al. (2009). Highly active antiretroviral therapy and 
the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin 
Oncol, Vol.27, No.6, pp. 884-890 
Powles, T., Thirwell, C., Newsom-Davis, T. et al. (2003). Does HIV adversely influence the 
outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer, 
Vol.89, No.3, pp. 457-459 
Richman, D.D., Fischl, M.A., Grieco, M.H. et al. (1987). The toxicity of azidothymidine (AZT) 
in the treatment of patients with AIDS and AIDS-related complex. A double-blind, 
placebo-controlled trial. N Engl J Med, Vol.317, No.4, pp. 192-197 
Rodriguez, R., Fontanesi, J., Meyer, J.L. et al. (1989). Normal-tissue effects of irradiation for 
Kaposi's sarcoma/AIDS. Front Radiat Ther Oncol, Vol.23, pp. 150-159 
Rosell, R., Moran, T., Queralt, C. et al. (2009). Screening for epidermal growth factor receptor 
mutations in lung cancer. N Engl J Med, Vol.361, No.10, pp. 958-967 
Rosen, L.S., Gordon, D., Kaminski, M. et al. (2003a). Long-term efficacy and safety of 
zoledronic acid compared with pamidronate disodium in the treatment of skeletal 
complications in patients with advanced multiple myeloma or breast carcinoma: a 
randomized, double-blind, multicenter, comparative trial. Cancer, Vol.98, No.8, pp. 
1735-1744 
Rosen, L.S., Gordon, D., Tchekmedyian, S. et al. (2003b). Zoledronic acid versus placebo in 
the treatment of skeletal metastases in patients with lung cancer and other solid 
tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung 
Cancer and Other Solid Tumors Study Group. J Clin Oncol, Vol.21, No.16, pp. 3150-
3157 
Rowinsky, E. & Donehower, R. 1997. Pharmacology of cancer chemotherapy-
antimicrotubule agents. In Cancer principles and practice of oncology, 5th ed. (Ed. De 
Vitavt, H., Rosembersa, Editors), pp. 467-483. Lippincott-Raven Publishers, 
Philadelphia 
Samet, J.M., Wiggins, C.L., Humble, C.G. et al. (1988). Cigarette smoking and lung cancer in 
New Mexico. Am Rev Respir Dis, Vol.137, No.5, pp. 1110-1113 
Sandler, A., Gray, R., Perry, M.C. et al. (2006). Paclitaxel-carboplatin alone or with 
bevacizumab for non-small-cell lung cancer. N Engl J Med, Vol.355, No.24, pp. 2542-
2550 
Saves, M., Chene, G., Ducimetiere, P. et al. (2003). Risk factors for coronary heart disease in 
patients treated for human immunodeficiency virus infection compared with the 
general population. Clin Infect Dis, Vol.37, No.2, pp. 292-298 
www.intechopen.com
 HIV and Lung Cancer   
 
413 
Scagliotti, G., Hanna, N., Fossella, F. et al. (2009). The differential efficacy of pemetrexed 
according to NSCLC histology: a review of two Phase III studies. Oncologist, Vol.14, 
No.3, pp. 253-263 
Scagliotti, G.V., Parikh, P., Von Pawel, J. et al. (2008). Phase III study comparing cisplatin 
plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients 
with advanced-stage non-small-cell lung cancer. J Clin Oncol, Vol.26, No.21, pp. 
3543-3551 
Schiller, J.H., Harrington, D., Belani, C.P. et al. (2002). Comparison of four chemotherapy 
regimens for advanced non-small-cell lung cancer. N Engl J Med, Vol.346, No.2, pp. 
92-98 
Sepkowitz, K.A. (2001). AIDS--the first 20 years. N Engl J Med, Vol.344, No.23, pp. 1764-1772 
Shepherd, F.A., Fossella, F.V., Lynch, T. et al. (2001). Docetaxel (Taxotere) shows survival 
and quality-of-life benefits in the second-line treatment of non-small cell lung 
cancer: a review of two phase III trials. Semin Oncol, Vol.28, No.1 Suppl 2, pp. 4-9 
Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T. et al. (2005). Erlotinib in previously 
treated non-small-cell lung cancer. N Engl J Med, Vol.353, No.2, pp. 123-132 
Silverberg, M.J., Chao, C., Leyden, W.A. et al. (2009). HIV infection and the risk of cancers 
with and without a known infectious cause. AIDS, Vol.23, No.17, pp. 2337-2345 
Silverberg, M.J., Neuhaus, J., Bower, M. et al. (2007). Risk of cancers during interrupted 
antiretroviral therapy in the SMART study. AIDS, Vol.21, No.14, pp. 1957-1963 
Souquet, P.J., Chauvin, F., Boissel, J.P. et al. (1993). Polychemotherapy in advanced non 
small cell lung cancer: a meta-analysis. Lancet, Vol.342, No.8862, pp. 19-21 
Spano, J.P., Massiani, M.A., Bentata, M. et al. (2004). Lung cancer in patients with HIV 
Infection and review of the literature. Med Oncol, Vol.21, No.2, pp. 109-115 
Sridhar, K.S., Flores, M.R., Raub, W.A., Jr. et al. (1992). Lung cancer in patients with human 
immunodeficiency virus infection compared with historic control subjects. Chest, 
Vol.102, No.6, pp. 1704-1708 
Stebbing, J. & Bower, M. (2006). Comparative pharmacogenomics of antiretroviral and 
cytotoxic treatments. Lancet Oncol, Vol.7, No.1, pp. 61-68 
Tan, B. & Ratner, L. (1997). The use of new antiretroviral therapy in combination with 
chemotherapy. Curr Opin Oncol, Vol.9, No.5, pp. 455-464 
Temel, J.S., Greer, J.A., Muzikansky, A. et al. (2010). Early palliative care for patients with 
metastatic non-small-cell lung cancer. N Engl J Med, Vol.363, No.8, pp. 733-742 
Tenholder, M.F. & Jackson, H.D. (1993). Bronchogenic carcinoma in patients seropositive for 
human immunodeficiency virus. Chest, Vol.104, No.4, pp. 1049-1053 
Tirelli, U., Spina, M., Sandri, S. et al. (2000). Lung carcinoma in 36 patients with human 
immunodeficiency virus infection. The Italian Cooperative Group on AIDS and 
Tumors. Cancer, Vol.88, No.3, pp. 563-569 
Tong, X., Li, K., Luo, Z. et al. (2009). Decreased TIP30 expression promotes tumor metastasis 
in lung cancer. Am J Pathol, Vol.174, No.5, pp. 1931-1939 
Toschi, E., Sgadari, C., Malavasi, L. et al. (2011). Human immunodeficiency virus protease 
inhibitors reduce the growth of human tumors via a proteasome-independent block 
of angiogenesis and matrix metalloproteinases. Int J Cancer, Vol.128, No.1, pp. 82-93 
Tsuya, A., Kurata, T., Tamura, K. et al. (2007). Skeletal metastases in non-small cell lung 
cancer: a retrospective study. Lung Cancer, Vol.57, No.2, pp. 229-232 
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
414 
Vajdic, C.M., Mcdonald, S.P., Mccredie, M.R. et al. (2006). Cancer incidence before and after 
kidney transplantation. JAMA, Vol.296, No.23, pp. 2823-2831 
Vallis, K.A. (1991). Glutathione deficiency and radiosensitivity in AIDS patients. Lancet, 
Vol.337, No.8746, pp. 918-919 
Von Pawel, J., Schiller, J.H., Shepherd, F.A. et al. (1999). Topotecan versus 
cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent 
small-cell lung cancer. J Clin Oncol, Vol.17, No.2, pp. 658-667 
Vyzula, R. & Remick, S.C. (1996). Lung cancer in patients with HIV-infection. Lung Cancer, 
Vol.15, No.3, pp. 325-339 
Washington, C.B., Duran, G.E., Man, M.C. et al. (1998). Interaction of anti-HIV protease 
inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured 
cells. J Acquir Immune Defic Syndr Hum Retrovirol, Vol.19, No.3, pp. 203-209 
Wistuba, Ii, Behrens, C., Milchgrub, S. et al. (1998). Comparison of molecular changes in 
lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA, Vol.279, 
No.19, pp. 1554-1559 
www.intechopen.com
HIV and AIDS - Updates on Biology, Immunology, Epidemiology
and Treatment Strategies
Edited by Dr. Nancy Dumais
ISBN 978-953-307-665-2
Hard cover, 694 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The continuing AIDS pandemic reminds us that despite the unrelenting quest for knowledge since the early
1980s, we have much to learn about HIV and AIDS. This terrible syndrome represents one of the greatest
challenges for science and medicine. The purpose of this book is to aid clinicians, provide a source of
inspiration for researchers, and serve as a guide for graduate students in their continued search for a cure of
HIV. The first part of this book, â€œFrom the laboratory to the clinic,â€ ​ and the second part, â€œFrom the
clinic to the patients,â€ ​ represent the unique but intertwined mission of this work: to provide basic and clinical
knowledge on HIV/AIDS.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yusuke Okuma, Naoki Yanagisawa, Yukio Hosomi, Atsushi Ajisawa and Masahiko Shibuya (2011). HIV and
Lung Cancer, HIV and AIDS - Updates on Biology, Immunology, Epidemiology and Treatment Strategies, Dr.
Nancy Dumais (Ed.), ISBN: 978-953-307-665-2, InTech, Available from: http://www.intechopen.com/books/hiv-
and-aids-updates-on-biology-immunology-epidemiology-and-treatment-strategies/hiv-and-lung-cancer
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
